
INOPASE
A medical device company developing wirelessly powered, closed-loop implantable neuromodulation for treating chronic neurological diseases.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
* | N/A | Early VC | |
Total Funding | 000k |
Related Content
INOPASE Inc., a medical device company established in 2021, is at the forefront of creating advanced solutions for chronic neurological diseases. The company was co-founded by Munemasa Sugimoto and Wang Yen Po.
Munemasa Sugimoto, the CEO, brings over a decade of experience from the healthcare sector, including roles at Novartis and CDI Medical, and as a Project Assistant Professor at the University of Tokyo. This background in both business and academia has been pivotal in shaping INOPASE's direction.
The company is focused on developing miniaturized, wirelessly powered, closed-loop neuromodulation devices. This technology is designed to offer personalized treatments by continuously monitoring physiological signals and adjusting stimulation in real-time. The primary applications for this technology are in treating conditions such as overactive bladder, fecal incontinence, and drug-resistant epilepsy.
INOPASE's business model revolves around the research, development, and commercialization of these medical devices. Their target market includes healthcare providers and patients who are seeking more effective and less invasive treatment options for chronic neurological conditions. By providing a more precise and adaptive therapeutic approach, the company aims to improve the quality of life for patients while also offering a cost-effective solution for healthcare systems.
Keywords: neuromodulation, medical devices, chronic neurological diseases, overactive bladder, epilepsy, wireless power, closed-loop stimulation, personalized treatment, healthcare technology, medical research